Ampersand-backed Alliance Pharma to buy LGC’s DDS

Alliance Pharma, which is backed by Ampersand Capital Partners, has agreed to acquire UK-based LGC's Drug Development Solutions business.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this